



Prior Authorization Request Administrative Information

Member information

Last name First name MI

Member ID Date of birth

Sex assigned at birth Female Male "X" or Intersex

Current gender Female Male Transgender male Transgender female Other

Place of residence Home Nursing facility Other

Race Ethnicity

Preferred spoken language Preferred written language

MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).

Plan contact information

Please indicate the member's MassHealth Plan and fax or submit this completed and signed form according to the Plan's contact information below.

MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, and Children's Medical Security Plan
<input type="checkbox"/> MassHealth Drug Utilization Review Program Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318
MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP)
<input type="checkbox"/> Fallon Health Online Prior Authorization: go.covermymeds.com/OptumRx Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033
<input type="checkbox"/> Health New England Online Prior Authorization: go.covermymeds.com/OptumRx Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545
<input type="checkbox"/> Mass General Brigham Health Plan Online Prior Authorization (Pharmacy Benefit Reviews): go.covermymeds.com/OptumRx Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555 Online Prior Authorization (Medical Specialty Reviews): provider.massgeneralbrighamhealthplan.org Medical Specialty Reviews: Fax: (888) 656-6671 - Tel: (833) 895-2611
<input type="checkbox"/> Tufts Health Plan Online Prior Authorization: point32health.promptpa.com Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985
<input type="checkbox"/> WellSense Health Plan Online Prior Authorization: wellsense.org/providers/ma/pharmacy/prior-authorizations Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822

Lung Cancer Agents

Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at www.mass.gov/druglist.

Medication information

Medication requested

- | | |
|---|--|
| <input type="checkbox"/> Alecensa (alectinib) | <input type="checkbox"/> Lorbrena (lorlatinib) |
| <input type="checkbox"/> Alunbrig (brigatinib) | <input type="checkbox"/> Lumakras (sotorasib) |
| <input type="checkbox"/> Augtyro (repotrectinib) | <input type="checkbox"/> Rybrevant (amivantamab-vmjw) ^{MB} |
| <input type="checkbox"/> Emrelis (telisotuzumab vedotin-tlly) ^{MB} | <input type="checkbox"/> Rybrevant Faspro (amivantamab/hyaluronidase-lpuj) ^{MB} |
| <input type="checkbox"/> Ensacove (ensartinib) | <input type="checkbox"/> Tabrecta (capmatinib) |
| <input type="checkbox"/> erlotinib | <input type="checkbox"/> Tagrisso (osimertinib) |
| <input type="checkbox"/> gefitinib | <input type="checkbox"/> Tepmetko (tepotinib) |
| <input type="checkbox"/> Gilotrif (afatinib) | <input type="checkbox"/> Vizimpro (dacomitinib) |
| <input type="checkbox"/> Hernexeos (zongertinib) | <input type="checkbox"/> Xalkori (crizotinib) |
| <input type="checkbox"/> Hyrnuo (sevabertinib) | <input type="checkbox"/> Zepzelca (lurbinectedin) ^{MB} |
| <input type="checkbox"/> Ibtrozi (taletrectinib) | <input type="checkbox"/> Zykadia (ceritinib) |
| <input type="checkbox"/> Krazati (adagrasib) | |
| <input type="checkbox"/> Lazcluze (lazertinib) | |

^{MB} This drug is available through the health care professional who administers the drug or in an outpatient or inpatient hospital setting. MassHealth does not pay for this drug to be dispensed through the retail pharmacy. If listed, PA does not apply through the acute hospital inpatient setting, unless on the APAD/APEC carve-out drug list, or in the emergency, trauma, or urgent acute hospital outpatient settings. Please refer to 130 CMR 433.408 for PA requirements for other health care professionals. Notwithstanding the above, this drug may be an exception to the unified pharmacy policy; please refer to respective MassHealth Accountable Care Partnership Plans (ACPPs) and Managed Care Organizations (MCOs) for PA status and criteria, if applicable.

Dose, frequency, and duration of medication requested

Height

Weight

Date

Please indicate prescriber specialty below.

Oncology Other

Will the requested agent be used as monotherapy for this indication? Yes No

If no, please list all other medications currently prescribed for the member that will be used concomitantly for this indication.

Please indicate billing preference. Pharmacy Prescriber in-office Hospital outpatient
If applicable, please also complete section for professionally administered medications at end of form.

Drug NDC (if known) or service code

Indication (Check all that apply or include ICD-10 code, if applicable.)

Lung cancer

- | | |
|--|--|
| <input type="checkbox"/> Non-small cell lung cancer (NSCLC) | <input type="checkbox"/> Small-cell lung cancer (SCLC) |
| <input type="checkbox"/> Adjuvant treatment for stage IB to IIIA | <input type="checkbox"/> Advanced or metastatic |
| <input type="checkbox"/> Advanced or metastatic | <input type="checkbox"/> Extensive-stage (ES-SCLC) |

Other Oncologic Indication

- | | |
|--|--|
| <input type="checkbox"/> Colorectal cancer | <input type="checkbox"/> Solid tumors |
| <input type="checkbox"/> Advanced or metastatic | <input type="checkbox"/> Systemic anaplastic large cell lymphoma |
| <input type="checkbox"/> Inflammatory myofibroblastic tumors (IMT) | <input type="checkbox"/> Other <input type="text"/> |
| <input type="checkbox"/> Pancreatic cancer | |
| <input type="checkbox"/> Advanced or metastatic | |

Please describe pertinent mutations or biomarkers.

- ALK-positive high c-MET protein overexpression EGFR G2032R HER2 (ERBB2)
 KRAS G12C MET exon 14 skipping ROS1 T790M resistance

Please describe details of pertinent mutations or biomarkers, including exon deletions or mutations, below.

Please describe the cell histology, if applicable.

Please describe the stage and severity of disease.

Has the member had persistent or recurring disease following surgery and/or radiation therapy? Yes No

Is the member a candidate for surgery and/or radiation?

Yes No. Please describe.

Section I. Please complete for all requests.

Please list any other prior trials. Please list the drug names, dates/duration of use and outcomes below.*

Drug name Dates/duration of use

Did the member experience any of the following? Adverse reaction Inadequate response Other
Briefly describe details of adverse reaction, inadequate response, or other.

Drug name Dates/duration of use

Did the member experience any of the following? Adverse reaction Inadequate response Other
Briefly describe details of adverse reaction, inadequate response, or other.

Drug name Dates/duration of use

Did the member experience any of the following? Adverse reaction Inadequate response Other
Briefly describe details of adverse reaction, inadequate response, or other.

Drug name

Dates/duration of use

Did the member experience any of the following? Adverse reaction Inadequate response Other

Briefly describe details of adverse reaction, inadequate response, or other.

** Please attach a letter documenting additional trials as necessary.*

Section II. Please complete for Xalkori pellet requests.

Does the member have a medical condition in which they are unable to swallow tablets/capsules?

Yes. Please provide details.

No. Please provide clinical rationale why conventional dosage forms cannot be used.

Section III. Please complete for requests for agents with a preferred alternative.

Please describe clinical rationale for use of the requested agent instead of the preferred alternative.

Section IV. Please complete for requests for quantities above quantity limits.

Please describe the clinical rationale for exceeding the quantity limit, including a detailed treatment plan.

Section V. Please include any other pertinent information (if needed).

Section VI. Please complete and provide documentation for exceptions to step therapy.

1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to, the member? Yes No

If yes, briefly describe details of contraindication, adverse reaction, or harm.

2. Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen?

Yes No

If yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.

3. Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?

Yes No

If yes, please provide details for the previous trial.

Drug name Dates/duration of use

Did the member experience any of the following? Adverse reaction Inadequate response

Briefly describe details of adverse reaction or inadequate response.

4. Is the member stable on the requested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse reaction in, or physical or mental harm to, the member?

Yes. Please provide details.

No

Please continue to next page and complete Prescriber and Provider Information section.

Prior Authorization Request Prescriber and Provider Information

Prescriber information

Last name*	<input type="text"/>	First name*	<input type="text"/>	MI	<input type="text"/>
NPI*	<input type="text"/>	Individual MH Provider ID	<input type="text"/>		
DEA No.	<input type="text"/>	Office Contact Name	<input type="text"/>		
Address	<input type="text"/>	City	<input type="text"/>	State	<input type="text"/>
		Zip	<input type="text"/>		
E-mail address	<input type="text"/>				
Telephone No.*	<input type="text"/>				
Fax No.* (Please provide fax number for PA response notification.)	<input type="text"/>				

* Required

Please also complete for professionally administered medications, if applicable.

Start date	<input type="text"/>	End date	<input type="text"/>		
Servicing prescriber/facility name	<input type="text"/>	<input type="checkbox"/>	Same as prescribing provider		
Servicing provider/facility address	<input type="text"/>				
Servicing provider NPI/tax ID No.	<input type="text"/>				
Name of billing provider	<input type="text"/>				
Billing provider NPI No.	<input type="text"/>				
Is this a request for recertification?	<input type="checkbox"/>	Yes	<input type="checkbox"/>	No	
CPT code	<input type="text"/>	No. of visits	<input type="text"/>	J code	<input type="text"/>
				No. of units	<input type="text"/>

Provider's attestation, signature, and date

I certify under the pains and penalties of perjury that I am either the prescribing provider or duly authorized to act on behalf of the provider identified in the Prescriber information section of this form. Any attached statement on letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Signature of provider or individual duly authorized to act on behalf of the provider:

Printed legal name and title of signatory above

<input type="text"/>	Date	<input type="text"/>
----------------------	------	----------------------

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)